Aclidinium bromide

Drug Profile

Aclidinium bromide

Alternative Names: Aclinidinium; Bretaris Genuair; Eklira Genuair; KRP-AB1102; LAS-34273; Tudorza Pressair; TudorzaGenuair

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Almirall-Prodesfarma
  • Developer Allergan; Almirall S.A.; AstraZeneca; Daewoong Pharmaceutical; Forest Laboratories; Kyorin Pharmaceutical
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Quinuclidines; Small molecules; Tropanes
  • Mechanism of Action Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • No development reported Asthma

Most Recent Events

  • 11 Sep 2017 AstraZeneca plans a phase I trial in Healthy volunteers in China (NCT03276052)
  • 17 Mar 2017 AstraZeneca and Circassia Pharmaceuticals agree to co-promote and co-develop aclidinium bromide in USA for chronic obstructive pulmonary disease
  • 13 Jan 2017 AstraZeneca and Parexel plan the phase III AVANT trial for Chronic obstructive pulmonary disease in India, Philippines, Taiwan and Vietnam (NCT03022097)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top